Kosei Tajima

939 total citations · 1 hit paper
15 papers, 706 citations indexed

About

Kosei Tajima is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Kosei Tajima has authored 15 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 2 papers in Epidemiology. Recurrent topics in Kosei Tajima's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Kosei Tajima is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Kosei Tajima collaborates with scholars based in Japan, United States and Switzerland. Kosei Tajima's co-authors include Nobuyuki Yamamoto, Kōichi Goto, Takashi Seto, Noboru Yamamoto, Isamu Okamoto, Makoto Nishio, Terufumi Kato, Shinji Atagi, Yukio Hosomi and Toyoaki Hida and has published in prestigious journals such as The Lancet Oncology, Annals of Oncology and BMJ Open.

In The Last Decade

Kosei Tajima

14 papers receiving 693 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 561 citations Takashi Seto, Terufumi Kato et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Kosei Tajima

Since Specialization

Citations

This map shows the geographic impact of Kosei Tajima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kosei Tajima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kosei Tajima more than expected).

Fields of papers citing papers by Kosei Tajima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kosei Tajima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kosei Tajima. The network helps show where Kosei Tajima may publish in the future.

Co-authorship network of co-authors of Kosei Tajima

This figure shows the co-authorship network connecting the top 25 collaborators of Kosei Tajima. A scholar is included among the top collaborators of Kosei Tajima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kosei Tajima. Kosei Tajima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients 2024 ·Advances in Therapy ·Akito Hata, Shunichiro Iwasawa, Yusuke Sasaki, Kosei Tajima, Yasutaka Chiba	1
2	A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients 2024 ·Advances in Therapy ·Motohiro Tamiya, Shunichiro Iwasawa, Yusuke Sasaki, Kosei Tajima, Yasutaka Chiba	0
3	Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer 2023 ·Translational Lung Cancer Research ·Makoto Nishio, Shinji Atagi, Kōichi Goto, Yukio Hosomi, Takashi Seto, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshige Yoshioka, Naoyuki Nogami, Makoto Maemondo, Seisuke Nagase, Isamu Okamoto, Noboru Yamamoto, (unknown), Kosei Tajima, Masahiro Fukuoka, Nobuyuki Yamamoto, Kazuto Nishio	3
4	Accuracy of algorithms to identify patients with a diagnosis of major cancers and cancer-related adverse events in an administrative database: a validation study in an acute care hospital in Japan 2022 ·BMJ Open ·Takashi Fujiwara, (unknown), Kosei Tajima, Akinori Yuri, Masahiro Iwasaku, Yasuyuki Okumura, Hironobu Tokumasu	10
5	Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice 2022 ·JTO Clinical and Research Reports ·Anjali Saqi, Kevin O. Leslie, André L. Moreira, Sylvie Lantuéjoul, Catherine A. Shu, Naiyer A. Rizvi, Joshua Sonett, Kosei Tajima, Shawn W. Sun, Barbara J. Gitlitz, Thomas V. Colby	17
6	Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study 2022 ·Thoracic Cancer ·Yukio Hosomi, Takashi Seto, Makoto Nishio, Kōichi Goto, Noboru Yamamoto, Isamu Okamoto, Kosei Tajima, Yusuke Kajihara, Nobuyuki Yamamoto	7
7	P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy 2018 ·Journal of Thoracic Oncology ·Naiyer A. Rizvi, David R. Gandara, Benjamin Solomon, (unknown), Alessandro Brunelli, Shawn W. Sun, Barbara J. Gitlitz, Kosei Tajima, Wei-Chun Lin, A. Sandler, Solange Peters	7
8	Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results 2017 ·Drug Safety ·Terufumi Kato, Takashi Seto, Makoto Nishio, Kōichi Goto, Noboru Yamamoto, Isamu Okamoto, Liang Tao, Wei Yu, (unknown), Kosei Tajima, Masahiko Shibata, Akihiro Seki, Nobuyuki Yamamoto	44
9	First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial 2017 ·Japanese Journal of Clinical Oncology ·Norikazu Masuda, Masato Takahashi, Kazuhiko Nakagami, Yasuhiro Okumura, Takahiro Nakayama, Nobuaki Sato, (unknown), Kosei Tajima, Masahiro Kashiwaba	8
10	Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer 2016 ·International Journal of Clinical Oncology ·Noboru Yamamoto, Kōichi Goto, Makoto Nishio, Kenichi Chikamori, Toyoaki Hida, Makoto Maemondo, Nobuyuki Katakami, Toshiyuki Kozuki, Hiroshige Yoshioka, Takashi Seto, Kosei Tajima, Tomohide Tamura	8
11	Erlotinib for Japanese Patients with Activating EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Combined Analyses from Two Phase II Studies 2016 ·Future Oncology ·Shinji Atagi, Kōichi Goto, Takashi Seto, Nobuyuki Yamamoto, Tomohide Tamura, Kosei Tajima, (unknown)	12
12	A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer 2016 ·Japanese Journal of Clinical Oncology ·Toru Sugiyama, Mika Mizuno, Yoichi Aoki, M Sakurai, Tadaaki Nishikawa, (unknown), Kosei Tajima, Nobuhiro Takeshima	23
13	420O Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non–small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysis 2015 ·Annals of Oncology ·Yukio Hosomi, Takashi Seto, Makoto Nishio, Kōichi Goto, Nobuyuki Yamamoto, Isamu Okamoto, Kosei Tajima, Nobuya Inagaki, Noboru Yamamoto	4
14	Combined analysis of two Phase II studies evaluating first-line erlotinib in NSCLC with EGFR mutation: JO22903/JO25567 2015 ·Annals of Oncology ·Shinji Atagi, Kōichi Goto, Takashi Seto, Nobuyuki Yamamoto, Tomohide Tamura, Kosei Tajima, (unknown)	1
15	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study breakdown → 2014 ·The Lancet Oncology ·Takashi Seto, Terufumi Kato, Makoto Nishio, Kōichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa, Seisuke Nagase, Isamu Okamoto, Takeharu Yamanaka, Kosei Tajima, (unknown), Masahiro Fukuoka, Nobuyuki Yamamoto	561

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact